Enlivex Reports 135 Of 182 Planned Patients Randomized And Dosed In Phase 2b Knee Osteoarthritis Trial Of Allocetra; Topline Six-Month Data Expected By Mid-2027

•      135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe
•      Topline six-month data expected by mid-2027
•      Phase 2b builds on positive three- and six-month Phase 1/2a data, which supported FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026

Nes-Ziona, Israel, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM in the Company’s Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The trial is actively recruiting at clinical sites in the United States, Denmark and Poland, and the Company expects to report topline six-month data by mid-2027.